Early Data On Cimzia® Shows Promise In Crohn’s Patients Without Infliximab

Datafrom the WELCOME trial presented at the third congress of the EuropeanCrohn’s and Colitis Organisation (ECCO) show that, at the six weekmark, Cimzia® (certolizumab pegol) is effective in Crohn’s patientsshowing intolerance or no response to infliximab. Crohn’sDisease (CD) is a gastrointestinal disorder which is indicated bychronicinflammation of the wall of the digestive tract, usually in the ileumor large intestines.

More: continued here

Filed under: Crohn on March 14th, 2008